bioMerieux, NuGen deal

The companies cross-licensed nucleic acid amplification technologies. BIM received non-exclusive rights to NuGen's amplification technologies to develop and market in vitro diagnostic tests. BIM plans to integrate NuGen's technologies to develop an automated microarray-based assay to diagnose cancer. NuGen received non-exclusive rights to BIM's linear amplification technologies using chimeric primers including OEM rights for the research market. ...